A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
M
Mohammad Abu Zaid, MD
Primary Investigator
Overview
This is a Phase 2, multicohort, open-label, multicenter study to determine whether treatment with JNJ-68284528 results in MRD negativity in adult subjects with multiple myeloma in various clinical settings. Two cohorts will run in parallel. Approximately 20 subjects will be enrolled in each cohort. The primary endpoint for all cohorts will be overall MRD negative rate.
Eligibility:
- Ages 18 and older
- Documented diagnosis of multiple myeloma
- Additional criteria must be met based on determination by Investigator and study requirements
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
multiple myeloma,cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
13 Apr 2023.
Study ID: 1909758243
